Concepedia

Author

Linda Morrow

Precision Research InstituteORCID

Also Known As

L A Morrow, L Morrow, L. A Morrow, L. A. Morrow, L. Morrow, LINDA A. MORROW, LINDA MORROW, Linda A Morrow, Linda A. Morrow, Linda Morrow

108

Publications

4.5K

Citations

31

H-Index

81

Concepts

All Affiliations

Precision Research InstituteProfil Institute for Clinical ResearchUniversity of MichiganEli Lilly (United States)Geriatric Research Education and Clinical Center
LM

About

Linda Morrow is an author at Precision Research Institute specializing in medicine, health sciences, and physiology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

17

1.8K

2

Health Sciences

11

11

1.6K

3

Education

1

1

10

4

Engineering

1

1

10

5

Management

1

1

34

Linda Morrow

×

62

Publications

4.2K

Citations

30

H-Index

YearCitations

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Sunder Mudaliar, Robert R. Henry, Arun J. Sanyal,

Gastroenterology

2013

906

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

Ralph A. DeFronzo, Marcus Hompesch, Sreeneeranj Kasichayanula,

Diabetes Care

2013

281

Recombinant Human Insulin-Like Growth Factor I Increases Insulin Sensitivity and Improves Glycemic Control in Type II Diabetes

Alan C. Moses, Simon C. Young, Linda Morrow,

Diabetes

1996

281

Comorbid Illness is Associated with Survival and Length of Hospital Stay in Patients with Chronic Disability

Paula A. Rochon, Jeffrey N. Katz, Linda Morrow,

Medical Care

1996

270

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin

Damayanthi Devineni, Linda Morrow, Marcus Hompesch,

Diabetes Obesity and Metabolism

2012

221

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Andrés Digenio, Richard L. Dunbar, Veronica J. Alexander,

Diabetes Care

2016

165

Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects

Amparo de la Peña, Matthew C. Riddle, Linda Morrow,

Diabetes Care

2011

121

Prevalence of Mutations in the Insulin Receptor Gene in Subjects With Features of the Type A Syndrome of Insulin Resistance

David E. Moller, Ohad Cohen, Yoshihiko Yamaguchi,

Diabetes

1994

113

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes

Julio Rosenstock, Richard M. Bergenstal, Thomas Blevins,

Diabetes Care

2012

96

Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study

Rohit Loomba, Eric Lawitz, Juan P. Frías,

˜The œLancet. Gastroenterology & hepatology

2022

91

Page 1